Update on AD:BTX 1204: recruitment completed and on track to...

Update on AD:

BTX 1204: recruitment completed and on track to report top line data in 1Q CY2020

During the quarter, Botanix completed patient recruitment for the BTX 1204 Phase 2 atopic dermatitis clinical study and top line data is expected to be released in 1Q CY2020. The 12-week randomised, double-blind and vehicle-controlled study evaluates the safety and efficacy of BTX 1204 in patients with moderate atopic dermatitis. 211 patients were enrolled across leading dermatology clinics across the US, Australia and New Zealand. This study leverages existing data from the BTX 1204 Phase 1b clinical study, which supports efficacy and safety potential.